Media Centre

Featured Media Release
 

05 Jul 2013 - New GSK additions to the National Immunisation Program (NIP)

The addition of two new vaccines to the NIP means that Australian children will have two less injections while still being protected against the same number of diseases.

 
 

Media Releases


Anoro® Ellipta® (umeclidinium/vilanterol) to be reimbursed in Australia for Chronic Obstructive Pulmonary Disease

GlaxoSmithKline (GSK) and Theravance, Inc. (NASDAQ: THRX) have welcomed news that Anoro Ellipta (umeclidinium/vilanterol) will be reimbursed via the Australian Pharmaceutical Benefits Scheme (PBS) as a long-term once-daily, maintenance...

01/12/2014

 

Breo® Ellipta® (fluticasone furoate/vilanterol) to be PBS listed as reimbursed treatment for asthma and COPD

Affordable treatment options for Australian patients with asthma and chronic obstructive pulmonary disease (COPD) are set to expand with GlaxoSmithKline (GSK) and Theravance, Inc. (NASDAQ: THRX) announcing the listing of Breo Ellipta on the...

01/12/2014

 

Incruse® Ellipta® (umeclidinium) to be reimbursed in Australia for Chronic Obstructive Pulmonary Disease

GlaxoSmithKline (GSK) has welcomed the listing of Incruse Ellipta (umeclidinium) on the Australian Pharmaceutical Benefits Scheme (PBS) from December 1st 2014 as a long term once-daily, maintenance bronchodilator treatment to relieve symptoms in...

01/12/2014

 

GSK leads Access to Medicines Index 2014

The Access to Medicines Index published today has ranked GSK top for the fourth consecutive time.

17/11/2014

 

GSK announces multi-million dollar investment in next generation manufacturing

GSK Australia has announced today it will be investing AUD$31 million in next generation manufacturing technology to expand its Boronia site in the outer eastern suburbs of Melbourne.

14/11/2014

 

GSK transitions to online versions of Consumer Medicine Information (CMI) leaflets for prescription only medicines

To ensure we provide the most up-to-date consumer medicine information (CMI) to patients, GSK will no longer be providing CMI leaflets in medicine packs, including sample packs.

10/11/2014

 

Plant drugs and snail venom: Revolutionary drug research wins GSK award

20-year research program acknowledged with prestigious $80,000 GSK Award for Research Excellence

06/11/2014

 

Pharmacy/Wholesaler level recall of two batches of Zovirax® Ophthalmic Ointment (aciclovir 3%)

GSK Australia, in consultation with the Therapeutic Goods Administration (TGA), is initiating a voluntary pharmacy/wholesaler level recall of two batches of Zovirax® Ophthalmic Ointment (aciclovir 3%).

27/10/2014

 

Indigenous and refugee programs win immunisation boost

GSK’s 2014 Immunisation Grants have been awarded to programs that are helping improve access and awareness of vaccination services for Indigenous and refugee communities.

14/10/2014

 

Arzerra® (ofatumumab) registered in Australia for first-line use in chronic lymphocytic leukaemia (CLL)...

GlaxoSmithKline announced today that the Therapeutic Goods Administration (TGA) has registered Arzerra® (ofatumumab), a human monoclonal antibody, in combination with chlorambucil or bendamustine for the treatment of patients in Australia with...

03/10/2014

1 2 3 4 5 6 7 8 9 10 11 >